Shire Surges After FDA Approves Xiidra for Dry-Eye Disease

Updated on
  • Xiidra is only treatment approved for both signs and symptoms
  • Analysts estimate sales will exceed $1 billion by 2022

Shire Plc rose to its highest level in 10 months in London after the U.S. Food and Drug Administration approved its Xiidra drops to treat dry-eye disease, the first treatment for the ailment to be approved in more than a decade.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.